Eric Duncavage, MD, explains how patients with AML can benefit from whole-genome sequencing testing at diagnosis and after treatment for minimal or measurable residual disease (MRD) assessment. Dr. Duncavage is the director of the sections of Hematopathology and Molecular Oncology and professor of Pathology and Immunology at Washington University in St. Louis. Read more about WGS in AML diagnosis and monitoring here: https://ilmnmkt.illumina.com/2016012194 #bloodcancerawareness Subscribe to the Illumina video channel http://www.youtube.com/subscription_center?add_user=IlluminaInc A global genomics leader, Illumina provides comprehensive next-generation sequencing solutions to the research, clinical, and applied markets. Through collaborative innovation, Illumina is fueling groundbreaking advancements in oncology, reproductive health, genetic disease, microbiology, agriculture, forensic science, and beyond. View customer spotlight videos https://www.youtube.com/playlist?list=PLKRu7cmBQlajfheLzgbI4S7xBn7IDbt79 View Illumina webinars https://www.youtube.com/playlist?list=PLKRu7cmBQlahpXlnrrXlQw9itVJ8yHwUZ View Illumina product videos https://www.youtube.com/playlist?list=PLKRu7cmBQlaj6YuZmkfxZcT9twqDgP2Xd View Illumina support videos https://www.youtube.com/playlist?list=PLKRu7cmBQlajbm2KGsICWb-JOnusJfYvM Facebook: https://www.facebook.com/illuminainc LinkedIn: https://www.linkedin.com/company/illu... Instagram: https://www.instagram.com/illuminainc/ Twitter: https://twitter.com/illumina